Top Markets
#1 Ontology Ontology +44.87%
#2 Bedrock Bedrock +24.56%
#3 Naoris Protocol Naoris Protocol +20.60%
#4 TARS AI TARS AI +20.15%
#5 bitcastle Token bitcastle Token +20.01%
#6 DeFiChain DeFiChain +19.51%
#7 ETHGas ETHGas +19.47%
#8 pippin pippin +19.32%
#9 Chrema Coin Chrema Coin +15.54%
#10 DUSK Network DUSK Network +15.52%
Coin of the day
Ontology Ontology
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Eli Lilly Eli Lilly

Eli Lilly

LLY
Kedudukan dalam Saham #15
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Harga Saham
$910.55
Modal Pasaran
$860.30B
Perubahan (1 hari)
0.44%
Perubahan (1 tahun)
5.28%
Negara
US
Perdagangan Eli Lilly (LLY)

Kategori

Healthcare
Nisbah P/E bagi Eli Lilly (LLY)
Nisbah P/E pada March 2026 TTM: 42.86
Menurut laporan kewangan dan harga saham terkini Eli Lilly, nisbah P/E semasa (TTM) ialah 42.86. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 65.65.
Sejarah nisbah P/E bagi Eli Lilly dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 42.86 -8.34%
2025 46.76 -28.78%
2024 65.65 -34.38%
2023 100.04 79.72%
2022 55.66 17.95%
2021 47.19 80.98%
2020 26.08 72.36%
2019 15.13 -58.89%
2018 36.80 -108.45%
2017 -435.34 -1,571.91%
2016 29.58 -23.51%
2015 38.67 20.64%
2014 32.05 163.64%
2013 12.16 -12.09%
2012 13.83 29.88%
2011 10.65 39.32%
2010 7.64 -15.64%
2009 9.06 -142.59%
2008 -21.27 -207.90%
2007 19.71 -7.29%
2006 21.27 -31.61%
2005 31.09 -8.50%
2004 33.98 15.00%
2003 29.55 16.81%
2002 25.30 -16.89%
2001 30.44 -7.43%
2000 32.88 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
 28.47 -33.59%
GB
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 21.88 -48.95%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 92.55 115.92%
US
Novartis AG Novartis AG
Novartis AG
NVS.US
 20.85 -51.36%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 15.77 -63.21%
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.